Fig. 3

RRM2 is upregulated in prostate cancer and associated with poor prognosis. A, B Analysis of RRM2 mRNA expression levels in prostate cancer datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. C Higher expression levels of RRM2 were observed in patients experiencing biochemical recurrence of prostate cancer (GSE120741). D–F Clinical data from The Cancer Genome Atlas database revealed a positive correlation between a high RRM2 expression level and a higher Gleason score, T stage, and serum PSA level, indicating an unfavourable clinical prognosis. G–I Higher expression levels of RRM2 were observed in prostate cancer tissue samples than in adjacent tissue samples. Additionally, RRM2 expression levels were significantly higher in castration-resistant prostate cancer (CRPC) tissues than in hormone-sensitive prostate cancer (HSPC) tissues. J Integrated analysis of multiple publicly available databases containing prognostic information showed that high expression of RRM2 indicated an unfavourable prognostic outcome in various survival cohorts